One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
PAVmed Inc.
PAVM · NCM · Healthcare · Medical Devices
Current price
$1.56
52-week range
$1.41 - $28.44
Market cap
$12.47M
Balance sheet
Distressed
-1,018.57x Concerning
Net debt $13.00M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 57.7% last year.
- Risk Return on equity was -64.8% last year — the company lost money on shareholders' equity.
What this company does
PAVmed Inc.
PAVmed Inc. is developing medical devices to help people, like a new way to treat carpal tunnel syndrome and a test to find a serious throat cancer early. Their money mostly comes from selling these new products, and it matters because it shows if their innovative health ideas are actually catching on with doctors and patients.
How the company got here
PAVmed Inc. was founded in 2014 by a group of surgeons and medical device executives with a mission to innovate and bring impactful medical technologies to market. The company's journey began with a focus on developing novel products to address unmet needs in healthcare. Over the years, PAVmed has strategically acquired and developed a pipeline of medical technologies, evolving into a commercial-stage company with a diversified portfolio spanning medical devices, diagnostics, and digital health. This evolution reflects a commitment to advancing patient care through disruptive medical technology.
What it actually does
PAVmed Inc. is a medical technology company that develops and commercializes innovative healthcare products. They focus on creating solutions that improve patient outcomes, enhance physician efficiency, and reduce healthcare costs. Their work involves a range of technologies, from minimally invasive surgical devices to advanced diagnostic tests and digital health platforms, all aimed at addressing significant unmet needs in the medical field.
Lucid Diagnostics (Diagnostics)
Lucid Diagnostics is PAVmed's subsidiary focused on cancer prevention through early detection. Their flagship products are the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device. The EsoCheck device collects cells from the esophagus, which are then analyzed by the EsoGuard test to detect precancerous conditions like Barrett's Esophagus and esophageal adenocarcinoma. This aims to prevent deaths from esophageal cancer by identifying the disease in its earliest stages, often without the need for invasive procedures like endoscopy. This segment represents a significant part of PAVmed's diagnostic efforts.
Veris Health (Digital Health)
Veris Health is PAVmed's digital health subsidiary, which focuses on enhancing personalized cancer care through remote patient monitoring. Their Veris Cancer Care Platform (Veris CCP) connects patients and clinicians, collecting real-time physiological data and patient-reported symptoms. This platform allows for better decision-making, proactive management of patient conditions, and more efficient healthcare delivery. Veris Health is also developing an implantable physiological monitor to further enhance remote patient monitoring capabilities, making it a key player in PAVmed's digital health strategy.
Medical Devices
PAVmed develops and commercializes a range of medical devices aimed at treating specific conditions. One key product is CarpX, a minimally invasive device for carpal tunnel syndrome that offers a less invasive alternative to traditional surgery. Another device is PortIO, an implantable intraosseous vascular access device designed for long-term use, potentially offering benefits over existing vascular access methods. The company also has the EsoCure Esophageal Ablation Device in its pipeline, intended for treating precancerous conditions of the esophagus. These devices represent PAVmed's core medical device business.
What management is betting on now
PAVmed's management is focused on advancing its diverse pipeline of medical technologies from development to commercialization. Key priorities include expanding the reach of its diagnostic tools like EsoGuard, further developing and integrating its digital health platform Veris CCP, and bringing its innovative medical devices such as CarpX and PortIO to market. The company is also leveraging a shared-services business model to achieve economies of scale and efficiently deploy resources across its various business lines, aiming for growth and profitability in the competitive medical technology sector.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-8.89M
FY2024 Q4
$90.00K
FY2025 Q1
$-1.59M
FY2025 Q2
$-1.19M
FY2025 Q3
$-899.00K
FY2025 Q4
$-1.56M
FY2026 Q1
$-2.64M
FY2026 Q2
$-2.68M
Revenue
$33.00K
Net income
$-5.38M
Diluted EPS
-0.87
Operating cash flow
$-2.66M
Free cash flow
$-2.68M
Fetching…
Sources
Revenue
$22.00K
Net income
$-60.00K
Diluted EPS
-4.42
Operating cash flow
$-2.62M
Free cash flow
$-2.64M
Fetching…
Sources
Revenue
$52.00K
Net income
$-1.26M
Diluted EPS
-4.94
Operating cash flow
$-1.55M
Free cash flow
$-1.56M
Fetching…
Sources
Revenue
$5.00K
Net income
$-5.38M
Diluted EPS
-0.29
Operating cash flow
$-896.00K
Free cash flow
$-899.00K
Fetching…
Sources
Revenue
$6.00K
Net income
$-11.92M
Diluted EPS
-0.74
Operating cash flow
$-1.18M
Free cash flow
$-1.19M
Fetching…
Sources
Revenue
$8.00K
Net income
$18.97M
Diluted EPS
0.34
Operating cash flow
$-1.58M
Free cash flow
$-1.59M
Fetching…
Sources
Revenue
$0.00
Net income
$1.43M
Diluted EPS
2.87
Operating cash flow
$94.00K
Free cash flow
$90.00K
Fetching…
Sources
Revenue
$1.00M
Net income
$64.40M
Diluted EPS
1.44
Operating cash flow
$-8.88M
Free cash flow
$-8.89M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.56
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net debt $13.0M. Interest coverage -1018.6x.
Net debt
$13.00M
Interest coverage
-1,018.57x
PAVmed Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 5 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Distressed
Worse cushion
Baseline
Better cushion
PAVM
BASELINE
PAVmed Inc.
Total debt $17.07M Interest coverage -1,018.57x This is the baseline the peer rows are being compared against.
Total debt $39.63M Interest coverage -1.15x Neither company has much profit cushion over interest right now.
Total debt $615.70K Interest coverage -348.20x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -9.76x Neither company has much profit cushion over interest right now.
Total debt $343.00K Interest coverage -5,153.50x Neither company has much profit cushion over interest right now.
Total debt $8.10M Interest coverage -20.46x Neither company has much profit cushion over interest right now.
What you should know
The case for and against PAVM
1 Reward
1 Risk
Rewards
-
Revenue grew 57.7% last year.
Risks
-
Return on equity was -64.8% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.66x
P/B
0.31x
P/S
111.37x
EV/EBITDA
-0.45x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
-220.5%
Operating margin
-21,278.8%
Net margin
0.0%
ROE
-64.8%
ROA
-39.7%
Health
Liquidity and balance-sheet strength
Debt / equity
0.88x
Current ratio
1.19x
Quick ratio
1.00x
Total debt
$17.07M
Total cash
$4.07M
Growth
How the business has been compounding
Revenue TTM
$112.00K
Revenue 5Y CAGR
-38.6%
EPS TTM
-14.20
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-7.73M
Free CF TTM
$-5.24M
FCF margin
-4,675.9%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—